Anastrozole Tablet
Product Images NDC 68071-3853

Product Visual Gallery

This gallery contains 8 technical images submitted to the FDA as part of the official labeling for Anastrozole (NDC 68071-3853). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Nucare Pharmaceuticals, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Pdp (68071 3853 8)

This is a pharmaceutical label for Anastrozole 1mg tablets, with information about the lot number, NDC number, expiration date, and manufacturer's details. It also includes a warning to keep the medication out of reach of children and instructions for storing at controlled temperatures. Additionally, there is a reminder to contact a doctor about any side effects and a reference to reporting side effects to the FDA.*

FDA Label Image

Chemical Structure (Anastrozole 01)

FDA Label Image

Figure 1 (Anastrozole 02)

This chart illustrates the disease-free survival rates over time for patients under two randomized treatments - anastrozole and tamoxifen. The number of patients at risk for each treatment group is also provided at various time points.*

FDA Label Image

Figure 2 (Anastrozole 03)

This text provides data on a randomized treatment comparing anastrozole and tamoxifen. It includes a graph showing the disease-free survival in months and the proportion of patients alive and disease-free over a period of 90 months. The number of patients at risk for each treatment group is also given.*

FDA Label Image

Figure 3 (Anastrozole 04)

FDA Label Image

Figure 4 (Anastrozole 05)

FDA Label Image

Figure 5 (Anastrozole 06)

The text is not-readable.*

FDA Label Image

Figure 6 (Anastrozole 07)

This text appears to be a table showing the progression of treatment with anastrozole and tamoxifen over a period of several months. The table includes the months from 0 to 40 and the number of individuals at risk for each month. The text also mentions "PROPORTION NOT PROGRESSING," which implies that it may be related to assessing treatment effectiveness or patient outcomes over time.*

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.